Filing Flows › Companies › Guardian Pharmacy Services › Analysis traps
Guardian Pharmacy Services (GRDN): analysis traps
Where its figures could mislead a reader, and what to check before taking them at face value · Data: Q3 2026, to Sep 30, 2026, filed Nov 5, 2026; rules v1.1
Guardian Pharmacy Services (GRDN): 1 rule of 10 triggered on the filings to Sep 30, 2026: FCF growth = the business improved. 1 to review; 4 with insufficient data; 2 not applicable. Each is a question to verify, with the normal explanation that would produce the same figures.
Check these first
FCF growth = the business improved Triggered · severity medium · confidence medium
Free cash flow rose $44M (+101%), from $43M to $87M, but working capital released $36M more cash than the year before and capital expenditure fell by $1M: 85% of the increase came from sources that need not repeat. Operating cash flow before working capital rose by $7M.
Innocent reading: An expansion programme finished, so capex fell back to maintenance levels for good.
A precise DCF value = the true value To review · confidence high
The DCF's point value is 21.21 a share (price 42.39); 71% of it is the terminal value, a number about years no one has seen. Moving operating margin by ±3 pts alone takes it from 12.58 to 29.85; across every method the research ran the range is -25 to 87. The value is a range; the decimals are not information.
Innocent reading: A stable, mature business with a narrow range of outcomes, where the point value is a fair summary.
Every rule
A01 FCF growth = the business improved Triggered severity medium · confidence medium
Free cash flow rose $44M (+101%), from $43M to $87M, but working capital released $36M more cash than the year before and capital expenditure fell by $1M: 85% of the increase came from sources that need not repeat. Operating cash flow before working capital rose by $7M.
The figures and how they are read
| Fiscal year before | FY2024 |
| Fiscal year | FY2025 |
| Operating cash flow, year before | $58M |
| Operating cash flow | $100M |
| Capex, year before | $15M |
| Capex | $13M |
| Free cash flow, year before | $43M |
| Free cash flow | $87M |
| Change in FCF | $44M |
| Change in capex | −$1M |
| Working capital: change in its cash contribution | $36M |
| Of which: capex cut | $1M |
| Of which: working capital released | $36M |
| Share of the increase that need not repeat | +85.1% |
| Operating cash flow before working capital: change | 6507000.00 |
FCF = operating cash flow − cash capex; ΔFCF = ΔOCF − ΔCapEx; the working-capital part is the change in the cash-bridge items (receivables, inventory, payables, accruals), with the sign of the cash flow statement
Source: FY2025 (cash flow statement, fiscal year) · FY2024 (cash flow statement, fiscal year before)
What would explain it innocently
- An expansion programme finished, so capex fell back to maintenance levels for good
- Suppliers agreed longer payment terms in a contract
- Inventory was brought down after a glut and will stay down
What to look for in the filing
- Maintenance capex (what it costs to keep the assets working)
- Supplier payment terms and any supply-chain financing
- Management's capex guidance for next year
What would show the trap does not apply
- Next year's FCF holds or rises with capex back at its earlier level and working capital no longer releasing cash
- The 10-K's capex guidance and the segment capex show the cut is a completed programme, not deferral
- The working-capital release matches a disclosed change in terms or a divestiture, not stretched payables or a collection push
Look again: next filing.
A07 Stock compensation added back = no economic cost Insufficient data
fewer than two fiscal years of stock compensation and share counts on file
B02 Receivables growing = future cash is certain Not triggered confidence medium
Receivables grew 1% against revenue -2% in Q3 2026; DSO 26 against a median of 26: collections are keeping pace with sales.
The figures and how they are read
| Quarter | Q3 2026 |
| Revenue, year over year | -1.7% |
| Receivables, year over year | +1.4% |
| Quarter before | Q2 2026 |
| Revenue y/y, quarter before | +2.2% |
| Receivables y/y, quarter before | +10.2% |
| Days sales outstanding | 26.2 |
| DSO, median of eight quarters | 25.6 |
| Receivables | $108M |
| Revenue | $371M |
receivables and revenue against the same quarter a year earlier; DSO = receivables / quarterly revenue × days, against the median of the eight quarters before
Source: Q3 2026 (receivables and revenue) · Q3 2025 (the same quarter a year earlier)
B08 Adjusted profit = economic profit Insufficient data
no reconciliation table read from the releases yet and fewer than three quarters with both an adjusted and a GAAP EPS
C02 Low net debt = no refinancing risk Insufficient data
no debt figure could be read from the balance sheet (the filing may tag it in other lines)
D03 EPS growth = profit growth Not triggered confidence high
EPS rose 88% and net income rose 90% in Q3 2026; the share count rose 0.8%: EPS growth follows profit growth.
The figures and how they are read
| Quarter | Q3 2026 |
| Quarter before | Q3 2025 |
| EPS, year before | $0.15 |
| EPS | $0.29 |
| Net income, year before | $10M |
| Net income | $19M |
| Diluted shares, year before | 63.4M shares |
| Diluted shares | 63.9M shares |
| EPS growth | +88.4% |
| Net income growth | +90.3% |
| Diluted shares: change | +0.8% |
| eps from profit | $0.14 |
| eps from share count | $0.00 |
EPS and net income against the same quarter a year earlier; the EPS bridge attributes the change to profit first, then to the share count (the order is fixed and disclosed)
Source: Q3 2026 (net income, diluted shares, EPS) · Q3 2025 (the same quarter a year earlier)
E02 Low P/E at a cyclical peak = undervalued Insufficient data
2 fiscal years of net income on file; a cycle needs five
E07 A precise DCF value = the true value To review confidence high
The DCF's point value is 21.21 a share (price 42.39); 71% of it is the terminal value, a number about years no one has seen. Moving operating margin by ±3 pts alone takes it from 12.58 to 29.85; across every method the research ran the range is -25 to 87. The value is a range; the decimals are not information.
The figures and how they are read
| dcf value | 21.21 |
| price | 42.39 |
| terminal value share | +70.9% |
| swing by input | Operating margin / ±3 pts / 12.58 / 29.85; Revenue growth (each year) / ±5 pts / 17.87 / 25.22; WACC / ±1 pt / 18.51 / 25.01; Tax rate / ±5 pts / 19.93 / 22.5 |
| range all methods | -25.37; 87.09 |
the DCF's point value against the share of it that is the terminal value and the value at each input moved by one step (growth ±5 pts, WACC ±1 pt, margin ±3 pts …); the range across every method the research ran
Source: 2026-11-08 (valuation research)
What would explain it innocently
- A stable, mature business with a narrow range of outcomes, where the point value is a fair summary
- The inputs that matter most are themselves well known (a regulated return, a long contract)
What to look for in the filing
- Which input you believe differs from the research's and why
- What the price implies for growth (the reverse DCF on the fair-value page)
What would show the trap does not apply
- The DCF's value is robust to the terminal growth and discount rate (the range's low end is still above the price)
- The company's cash flows over the next three years track the DCF's early years
Look again: next filing.
J06 A bank's low P/E and high profit = safe Not applicable
not a bank
J08 A REIT's low net income = the dividend is unsafe Not applicable
not a REIT
What the statuses mean
Triggered: the filings show the pattern; read the normal explanations and the missing evidence before concluding anything. To review: one quarter or a weak signal; a reader's judgement, not a pattern. Not triggered: the pattern is absent on these figures. Insufficient data: the filings read so far do not hold what the rule needs; this is not a clean bill. Not applicable: the rule is not meant for this kind of company (a bank's working capital, a loss-making quarter's EPS growth). Out of date: the latest filing is more than fifteen months old.
Severity is what the pattern could mean for cash, value or solvency; confidence is how reliable the inputs and the reading are. The two are kept apart.
Record a view
A reader's judgement, grounds, what would change it and the next review; kept in the browser (needs JavaScript).
Every rule and the companies it triggers on → Guardian Pharmacy Services: cash flow →
Each rule reads the company's own filings by a fixed formula and says what would explain the same figures innocently. A triggered rule is a question to verify, not a finding of manipulation, and not a view on the stock. Missing data is shown as missing, never as clear. Not investment advice.